Long-term outcome of patients with macroprolactinomas initially treated with dopamine agonists

European Journal of Internal Medicine

Volumn 20, Issue 4, 2009, Pages 387-393

  Kars, Marleen ^a   Pereira, Alberto M ^a   Smit, Johannes W ^a   Romijn, Johannes A ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Dopamine agonist; Long term follow up; Macroprolactinoma; Radiotherapy; Surgery

Indexed keywords

BROMOCRIPTINE; CABERGOLINE; DOPAMINE RECEPTOR STIMULATING AGENT; PROLACTIN; QUINAGOLIDE; TERGURIDE;

ADULT; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DIZZINESS; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FATIGUE; FEMALE; HEADACHE; HUMAN; HYPOGONADISM; HYPOPITUITARISM; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MORTALITY; NAUSEA; ORTHOSTATIC HYPOTENSION; PROLACTINOMA; TRANSSPHENOIDAL SURGERY; TREATMENT OUTCOME; TUMOR REGRESSION; VERTIGO; VISUAL FIELD DEFECT;

ADULT; DOPAMINE AGONISTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPOPITUITARISM; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PITUITARY NEOPLASMS; PREVALENCE; PROLACTINOMA; REMISSION INDUCTION; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 67349268969     PISSN: 09536205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejim.2008.11.012     Document Type: Article

References (44)

1. Ciccarelli A., Daly A.F., and Beckers A. The epidemiology of prolactinomas. Pituitary 8 (2005) 3-6
2. Daly A.F., Rixhon M., Adam C., Dempegioti A., Tichomirowa M.A., and Beckers A. High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. J Clin Endocrinol Metab 91 (2006) 4769-4775
3. Schlechte J.A. Clinical practice. Prolactinoma. N Engl J Med 349 (2003) 2035-2041
4. Aron D.C., and Howlett T.A. Pituitary incidentalomas. Endocrinol Metab Clin North Am 29 (2000) 205-221
5. Gillam M.P., Molitch M.E., Lombardi G., and Colao A. Advances in the treatment of prolactinomas. Endocr Rev 27 (2006) 485-534
6. Casanueva F.F., Molitch M.E., Schlechte J.A., Abs R., Bonert V., Bronstein M.D., et al. Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin Endocrinol (Oxf) 65 (2006) 265-273
7. Bevan J.S., Webster J., Burke C.W., and Scanlon M.F. Dopamine agonists and pituitary tumor shrinkage. Endocr Rev 13 (1992) 220-240
8. Verhelst J., Abs R., Maiter D., van den B.A., Vandeweghe M., Velkeniers B., et al. Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients. J Clin Endocrinol Metab 84 (1999) 2518-2522
9. Molitch M.E. Medical management of prolactin-secreting pituitary adenomas. Pituitary 5 (2002) 55-65
10. Schlechte J.A. Long-term management of prolactinomas. J Clin Endocrinol Metab 92 (2007) 2861-2865
11. Hamilton D.K., Vance M.L., Boulos P.T., and Laws E.R. Surgical outcomes in hyporesponsive prolactinomas: analysis of patients with resistance or intolerance to dopamine agonists. Pituitary 8 (2005) 53-60
12. Losa M., Mortini P., Barzaghi R., Gioia L., and Giovanelli M. Surgical treatment of prolactin-secreting pituitary adenomas: early results and long-term outcome. J Clin Endocrinol Metab 87 (2002) 3180-3186
13. Ferrari C., Paracchi A., Mattei A.M., de V.S., D'Alberton A., and Crosignani P. Cabergoline in the long-term therapy of hyperprolactinemic disorders. Acta Endocrinol (Copenh) 126 (1992) 489-494
14. Cannavo S., Curto L., Squadrito S., Almoto B., Vieni A., and Trimarchi F. Cabergoline: a first-choice treatment in patients with previously untreated prolactin-secreting pituitary adenoma. J Endocrinol Invest 22 (1999) 354-359
15. Di Sarno A., Landi M.L., Marzullo P., Di Somma C., Pivonello R., Cerbone G., et al. The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas. Clin Endocrinol (Oxf) 53 (2000) 53-60
16. Passos V.Q., Souza J.J., Musolino N.R., and Bronstein M.D. Long-term follow-up of prolactinomas: normoprolactinemia after bromocriptine withdrawal. J Clin Endocrinol Metab 87 (2002) 3578-3582
17. Colao A., Di Sarno A., Cappabianca P., Di Somma C., Pivonello R., and Lombardi G. Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia. N Engl J Med 349 (2003) 2023-2033
18. Chattopadhyay A., Bhansali A., and Masoodi S.R. Long-term efficacy of bromocriptine in macroprolactinomas and giant prolactinomas in men. Pituitary 8 (2005) 147-154
19. Berinder K., Stackenas I., Akre O., Hirschberg A.L., and Hulting A.L. Hyperprolactinaemia in 271 women: up to three decades of clinical follow-up. Clin Endocrinol (Oxf) 63 (2005) 450-455
20. Wu Z.B., Yu C.J., Su Z.P., Zhuge Q.C., Wu J.S., and Zheng W.M. Bromocriptine treatment of invasive giant prolactinomas involving the cavernous sinus: results of a long-term follow up. J Neurosurg 104 (2006) 54-61
21. Kars M., Roelfsema F., Romijn J.A., and Pereira A.M. Malignant prolactinoma: case report and review of the literature. Eur J Endocrinol 155 (2006) 523-534
22. Colao A., Di Sarno A., Landi M.L., Scavuzzo F., Cappabianca P., Pivonello R., et al. Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients. J Clin Endocrinol Metab 85 (2000) 2247-2252
23. Colao A., Di Sarno A., Landi M.L., Cirillo S., Sarnacchiaro F., Facciolli G., et al. Long-term and low-dose treatment with cabergoline induces macroprolactinoma shrinkage. J Clin Endocrinol Metab 82 (1997) 3574-3579
24. Colao A., Vitale G., Cappabianca P., Briganti F., Ciccarelli A., De Rosa M., et al. Outcome of cabergoline treatment in men with prolactinoma: effects of a 24-month treatment on prolactin levels, tumor mass, recovery of pituitary function, and semen analysis. J Clin Endocrinol Metab 89 (2004) 1704-1711
25. Molitch M.E., Elton R.L., Blackwell R.E., Caldwell B., Chang R.J., Jaffe R., et al. Bromocriptine as primary therapy for prolactin-secreting macroadenomas: results of a prospective multicenter study. J Clin Endocrinol Metab 60 (1985) 698-705
26. Van 't Verlaat J.W., Croughs R.J., Hendriks M.J., and Bosma N.J. Results of primary treatment with bromocriptine of prolactinomas with extrasellar extension. Can J Neurol Sci 17 (1990) 71-73
27. Van 't Verlaat J.W., and Croughs R.J. Withdrawal of bromocriptine after long-term therapy for macroprolactinomas; effect on plasma prolactin and tumour size. Clin Endocrinol (Oxf) 34 (1991) 175-178
28. Homburg R., West C., Brownell J., and Jacobs H.S. A double-blind study comparing a new non-ergot, long-acting dopamine agonist, CV 205-502, with bromocriptine in women with hyperprolactinaemia. Clin Endocrinol (Oxf) 32 (1990) 565-571
29. Schultz P.N., Ginsberg L., McCutcheon I.E., Samaan N., Leavens M., and Gagel R.F. Quinagolide in the management of prolactinoma. Pituitary 3 (2000) 239-249
30. Colao A., De Rosa M., Sarnacchiaro F., Di Sarno A., Landi M.L., Iervolino E., et al. Chronic treatment with CV 205-502 restores the gonadal function in hyperprolactinemic males. Eur J Endocrinol 135 (1996) 548-552
31. Van der Lely A.J., Brownell J., and Lamberts S.W. The efficacy and tolerability of CV 205-502 (a nonergot dopaminergic drug) in macroprolactinoma patients and in prolactinoma patients intolerant to bromocriptine. J Clin Endocrinol Metab 72 (1991) 1136-1141
32. Vance M.L., Lipper M., Klibanski A., Biller B.M., Samaan N.A., and Molitch M.E. Treatment of prolactin-secreting pituitary macroadenomas with the long-acting non-ergot dopamine agonist CV 205-502. Ann Intern Med 112 (1990) 668-673
33. Van 't Verlaat J.W., Croughs R.J., and Brownell J. Treatment of macroprolactinomas with a new non-ergot, long-acting dopaminergic drug, CV 205-502. Clin Endocrinol (Oxf) 33 (1990) 619-624
34. Di Sarno A., Landi M.L., Cappabianca P., Di Salle F., Rossi F.W., Pivonello R., et al. Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy. J Clin Endocrinol Metab 86 (2001) 5256-5261
35. Colao A., Di Sarno A., Sarnacchiaro F., Ferone D., Di Renzo G., Merola B., et al. Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment. J Clin Endocrinol Metab 82 (1997) 876-883
36. Molitch M.E. Pharmacologic resistance in prolactinoma patients. Pituitary 8 (2005) 43-52
37. Biermasz N.R., Van Dulken H., and Roelfsema F. Ten-year follow-up results of transsphenoidal microsurgery in acromegaly. J Clin Endocrinol Metab 85 (2000) 4596-4602
38. Pereira A.M., van Aken M.O., Van Dulken H., Schutte P.J., Biermasz N.R., Smit J.W., et al. Long-term predictive value of postsurgical cortisol concentrations for cure and risk of recurrence in Cushing's disease. J Clin Endocrinol Metab 88 (2003) 5858-5864
39. Laws E.R., Sheehan J.P., Sheehan J.M., Jagnathan J., Jane Jr. J.A., and Oskouian R. Stereotactic radiosurgery for pituitary adenomas: a review of the literature. J Neurooncol 69 (2004) 257-272
40. Minniti G., Traish D., Ashley S., Gonsalves A., and Brada M. Fractionated stereotactic conformal radiotherapy for secreting and nonsecreting pituitary adenomas. Clin Endocrinol (Oxf) 64 (2006) 542-548
41. Tsang R.W., Brierley J.D., Panzarella T., Gospodarowicz M.K., Sutcliffe S.B., and Simpson W.J. Role of radiation therapy in clinical hormonally-active pituitary adenomas. Radiother Oncol 41 (1996) 45-53
42. Becker G., Kocher M., Kortmann R.D., Paulsen F., Jeremic B., Muller R.P., et al. Radiation therapy in the multimodal treatment approach of pituitary adenoma. Strahlenther Onkol 178 (2002) 173-186
43. Kars M., Delgado V., Holman E.R., Feelders R.A., Smit J.W., Romijn J.A., et al. Aortic valve calcification and mild tricuspid regurgitation but no clinical heart disease after 8 years of dopamine agonist therapy for prolactinoma. J Clin Endocrinol Metab 93 (2008) 3348-3356
44. Kars M., Pereira A.M., Bax J.J., and Romijn J.A. Cabergoline and cardiac valve disease in prolactinoma patients: additional studies during long-term treatment are required. Eur J Endocrinol 159 (2008) 363-367